Grifols, S.A. (NASDAQ:GRFS) Shares Purchased by Hantz Financial Services Inc.

Hantz Financial Services Inc. raised its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 23.5% during the third quarter, Holdings Channel.com reports. The institutional investor owned 241,812 shares of the biotechnology company’s stock after buying an additional 45,997 shares during the period. Hantz Financial Services Inc.’s holdings in Grifols were worth $2,147,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in GRFS. Brandes Investment Partners LP raised its stake in Grifols by 8.7% in the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock valued at $117,242,000 after purchasing an additional 1,481,924 shares during the last quarter. Black Creek Investment Management Inc. raised its position in shares of Grifols by 7.7% in the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock valued at $77,799,000 after buying an additional 881,155 shares during the last quarter. Armistice Capital LLC lifted its stake in shares of Grifols by 18.7% during the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after buying an additional 1,244,000 shares during the period. Whitebox Advisors LLC boosted its position in Grifols by 45.6% during the second quarter. Whitebox Advisors LLC now owns 2,702,390 shares of the biotechnology company’s stock worth $17,039,000 after acquiring an additional 846,940 shares during the last quarter. Finally, Sei Investments Co. grew its stake in Grifols by 4.7% in the 2nd quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock worth $13,931,000 after acquiring an additional 100,131 shares during the period.

Grifols Stock Performance

NASDAQ GRFS opened at $6.99 on Friday. The company has a 50-day moving average of $8.76 and a 200-day moving average of $8.10. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 12 month low of $5.30 and a 12 month high of $12.15.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.